11
Pelvic RT plus concurrent low-dose
platinum-based chemotherapy plus
brachytherapy
(EB , H, S)
Pelvic RT plus concurrent low-
dose platinum-based chemotherapy
plus brachytherapy plus adjuvant
hysterectomy; adjuvant hysterectomy is
not recommended except if evidence of
residual disease
(EB, I, W)
Pelvic RT plus concurrent low-dose
platinum-based chemotherapy plus
brachytherapy
(EB , H, S)
Pelvic RT plus concurrent low-
dose platinum-based chemotherapy
plus brachytherapy plus adjuvant
hysterectomy; adjuvant hysterectomy is
not recommended except if evidence of
residual disease
(EB, I, W)
Radical hysterectomy plus PLND ± para-
aortic LN samplingc and adjuvant RT or
chemoRT if needed
(EB, L, W)
Radical hysterectomy plus PLND ±
para-aortic LN sampling and adjuvant
RT or chemoRT if needed (plus RT ±
concurrent low-dose platinum-based
chemotherapy aer hysterectomy if risk
factors)
c
(EB/CB, L, W)
Enhanced Maximal
